Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Free Radical Biology & Medicine

• Publication date

  2009-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.freeradbiomed.2009.07.013PMID 19616617PMCID PMC3690578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protocol for the MPTP mouse model of Parkinson's disease

  2007cited by this paper
• DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1.

  2007cited by this paper
• PARP-1 activation in the ERK signaling pathway.

  2007cited by this paper
• High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease

  2006cited by this paper
• Catechol Quinones of Estrogens in the Initiation of Breast, Prostate, and Other Human Cancers

  2006cited by this paper
• Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function"

  2005cited by this paper
• A Shuttle Mechanism for DNA‐Protein Interactions

  2005cited by this paper
• Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling.

  2004cited by this paper
• S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function

  2004cited by this paper
• Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

  2003cited by this paper
• Aging and Genome Maintenance: Lessons from the Mouse?

  2003cited by this paper
• Parkinson's Disease Mechanisms and Models

  2003cited by this paper
• Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease

  2003cited by this paper
• Neurological diseases: Targeting programmed cell death in neurodegenerative diseases

  2003cited by this paper
• Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration

  2003cited by this paper
• The mouse brain in stereotaxic coordinates

  2003cited by this paper
• DNA single-strand break repair and spinocerebellar ataxia.

  2003cited by this paper
• Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.

  2002cited by this paper
• p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism

  2002cited by this paper
• Mitochondrial DNA Deletions/Rearrangements in Parkinson Disease and Related Neurodegenerative Disorders

  2002cited by this paper
• Detection of Poly(ADP-ribose) Polymerase Activation in Oxidatively Stressed Cells and Tissues Using Biotinylated NAD Substrate

  2002cited by this paper
• The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety

  2001cited by this paper
• MPTP: a review of its mechanisms of neurotoxicity

  2001cited by this paper
• Spontaneous long‐term compensatory dopaminergic sprouting in MPTP‐treated mice

  2000cited by this paper
• Enhanced Mitochondrial DNA Repair and Cellular Survival after Oxidative Stress by Targeting the Human 8-Oxoguanine Glycosylase Repair Enzyme to Mitochondria*

  2000cited by this paper
• Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

  1999cited by this paper
• Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons.

  1999cited by this paper
• Morphology and compartmental location of cells exhibiting DNA damage after quinolinic acid injections into rat striatum

  1999cited by this paper
• Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.

  1999cited by this paper
• Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

  1999cited by this paper
• Mass Spectrometric Quantification of 3-Nitrotyrosine, ortho-Tyrosine, and o,o′-Dityrosine in Brain Tissue of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Mice, a Model of Oxidative Stress in Parkinson's Disease*

  1999cited by this paper
• Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1998cited by this paper
• Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra

  1997cited by this paper
• Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration.

  1997cited by this paper
• Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice.

  1996cited by this paper
• Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

  1996cited by this paper
• Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase

  1995cited by this paper
• Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

  1995cited by this paper
• Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.

  1991cited by this paper
• The fine structure of the nervous system

  1991cited by this paper
• Histochemical detection of DNA strand scissions in mammalian cells by in situ nick translation.

  1985cited by this paper
• A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase.

  1982cited by this paper
• Bovine thymus poly(adenosine diphosphate ribose) polymerase. Physical properties and binding to DNA.

  1980cited by this paper
• Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks.

  1980cited by this paper

• Crosstalk between DNA damage and cGAS-STING immune pathway drives neuroinflammation and dopaminergic neurodegeneration in Parkinson's disease.

  2025cites this paper
• The Mitochondrial Connection in Parkinson's Disease.

  2025cites this paper
• DNA Damage-Mediated Neurotoxicity in Parkinson’s Disease

  2023cites this paper
• Diverging Parkinson’s Disease Pathology between patient-derived GBAN370S, LRRK2G2019S and engineered SNCAA53T iPSC-derived Dopaminergic Neurons

  2023cites this paper
• Chrysophanol facilitates long-term neurological recovery through limiting microglia-mediated neuroinflammation after ischemic stroke in mice.

  2022cites this paper
• Nitrosative stress in Parkinson’s disease

  2022cites this paper
• A Major Diplotaxis harra-Derived Bioflavonoid Glycoside as a Protective Agent against Chemically Induced Neurotoxicity and Parkinson’s Models; In Silico Target Prediction; and Biphasic HPTLC-Based Quantification

  2022cites this paper
• The potential role of metformin in the treatment of Parkinson's disease

  2020cites this paper
• Perillyl Alcohol Mitigates Behavioural Changes and Limits Cell Death and Mitochondrial Changes in Unilateral 6-OHDA Lesion Model of Parkinson’s Disease Through Alleviation of Oxidative Stress

  2020cites this paper
• Curcumin protects rat hippocampal neurons against pseudorabies virus by regulating the BDNF/TrkB pathway

  2020cites this paper
• Mitochondrial Proteins in the Development of Parkinson's Disease.

  2019cites this paper
• Cerebral dopamine neurotrophic factor–deficiency leads to degeneration of enteric neurons and altered brain dopamine neuronal function in mice

  2019cites this paper
• Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease

  2018cites this paper
• Anti-inflammatory effect of oleuropein on microglia through regulation of Drp1-dependent mitochondrial fission.

  2017cites this paper
• Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity

  2017cites this paper
• Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?

  2017cites this paper
• Toxin-Induced Parkinson’s Disease Models

  2017cites this paper
• Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress

  2017cites this paper
• Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis

  2017cites this paper
• Chrysophanol suppresses pro-inflammatory response in microglia via regulation of Drp1-dependent mitochondrial fission

  2017cites this paper
• Neurodegeneration caused by accumulation of an oxidized base lesion, 8-oxoguanine, in nuclear and mitochondrial DNA: from animal models to human diseases.

  2017cites this paper
• An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease.

  2016cites this paper
• DNA Double Strand Breaks: A Common Theme in Neurodegenerative Diseases.

  2016cites this paper
• l‐DOPA‐induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

  2016cites this paper
• Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress.

  2016cites this paper
• Exercise and Nutritional Benefits in PD: Rodent Models and Clinical Settings.

  2016cites this paper
• Type-2 cannabinoid receptors in neurodegeneration.

  2016cites this paper
• Selenium reduces bradykinesia and DNA damage in a rat model of Parkinson's disease.

  2015cites this paper
• Efeitos do selênio sobre a neurotoxicidade, genotoxicidade, função locomotora e alterações teciduais em ratos wistar submetidos a um modelo experimental da doença de Parkinson induzido por paraquat

  2015cites this paper
• neuroblastoma cells with the state space model

  2015cites this paper
• Genome-wide transcriptional comparison of MPP + treated human neuroblastoma cells with the state space model

  2015cites this paper
• MPTP’s Pathway of Toxicity Indicates Central Role of Transcription Factor SP1

  2015cites this paper
• Dynamic changes in the distribution and time course of blood-brain barrier-permeative nitroxides in the mouse head with EPR imaging: visualization of blood flow in a mouse model of ischemia.

  2014cites this paper
• Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo

  2014cites this paper
• Inflammatory response in Parkinson's disease (Review).

  2014cites this paper
• Corals and Their Potential Applications to Integrative Medicine

  2014cites this paper
• Inflammatory Cells and Cytokines in the Olfactory Bulb of a Rat Model of Neuroinflammation; Insights into Neurodegeneration?

  2013cites this paper
• Effects of intravenous human umbilical cord blood CD34+ stem cell therapy versus levodopa in experimentally induced Parkinsonism in mice

  2013cites this paper
• Does Restraining Nitric Oxide Biosynthesis Rescue from Toxins-Induced Parkinsonism and Sporadic Parkinson's Disease?

  2013cites this paper
• The Role of β-Adrenergic Blockers in Parkinson’s Disease

  2013cites this paper
• Uncovering novel actors in astrocyte–neuron crosstalk in Parkinson's disease: the Wnt/β‐catenin signaling cascade as the common final pathway for neuroprotection and self‐repair

  2013cites this paper
• Pesticides, Microglial NOX2, and Parkinson's Disease

  2013cites this paper
• Omega‐3 fatty acid eicospentaenoic acid attenuates MPP+‐induced neurodegeneration in fully differentiated human SH‐SY5Y and primary mesencephalic cells

  2013influential citation
• Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

  2013cites this paper
• Role of ATF4 in Neuronal Death Mediated by DNA Damage, Endoplasmic Reticulum Stress and Ischemia-Hypoxia

  2013cites this paper
• PGE2 EP1 Receptor Deletion Attenuates 6-OHDA-Induced Parkinsonism in Mice: Old Switch, New Target

  2013cites this paper
• Mitochondrial biology and Parkinson's disease.

  2012cites this paper
• A Role for Activated Microglia and Peroxynitrite in Lewy Body Diseases – Implications for Prevention and Control

  2012cites this paper
• Neuroprotection by Silencing iNOS Expression in a 6-OHDA Model of Parkinson’s Disease

  2012influential citation
• Mitochondria and Programmed Cell Death in Parkinson's Disease: Apoptosis and Beyond

  2012influential citation
• Polycyclic Cage Structures as Lipophilic Scaffolds for Neuroactive Drugs

  2012cites this paper
• Effects of ginsenoside Re on LPS-induced inflammatory mediators in BV2 microglial cells

  2012cites this paper
• MPTP and Oxidative Stress: It’s Complicated!

  2011cites this paper
• Triptolide Down‐regulates COX‐2 Expression and PGE2 Release by Suppressing the Activity of NF‐κB and MAP kinases in Lipopolysaccharide‐treated PC12 Cells

  2011cites this paper
• The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B

  2011cites this paper
• Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

  2011cites this paper
• Kinetic study on the effects of extremely low frequency electromagnetic field on catalase, cytochrome P450 and inducible nitric oxide synthase in human HaCaT and THP-1 cell lines.

  2011cites this paper
• Neuroprotection by marine-derived compound, 11-dehydrosinulariolide, in an in vitro Parkinson’s model: a promising candidate for the treatment of Parkinson’s disease

  2011cites this paper
• Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

  2010cites this paper
• Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.

  2010cites this paper
• Glia as a turning point in the therapeutic strategy of Parkinson's disease.

  2010cites this paper
• Nitric oxide production during cerebral ischemia and reperfusion in eNOS- and nNOS-knockout mice.

  2010cites this paper
• Activation of ataxia telangiectasia muted under experimental models and human Parkinson’s disease

  2010cites this paper
• Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins

  2010cites this paper